No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MNMD240621C14000
- 0.01
- -0.09-90.00%
15min DelayClose Jun 14 15:50 ET
0.01High0.01Low
0.01Open0.10Pre Close1 Volume182 Open Interest14.00Strike Price1.00Turnover206.11%IV81.01%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0153Delta0.0192Gamma774.00Leverage Ratio-0.0055Theta0.0000Rho11.82Eff Leverage0.0004Vega
Intraday
- 5D
- 1D
News
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?
Leerink Partners Maintains Mind Medicine(MNMD.US) With Buy Rating
Leerink Partners analyst Rudy Li maintains $Mind Medicine(MNMD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 36.8% and a total average return of 11.2% over the p
Baird Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $27
Baird analyst Joel Beatty maintains $Mind Medicine(MNMD.US)$ with a buy rating, and maintains the target price at $27.According to TipRanks data, the analyst has a success rate of 46.7% and a total av
Don't Freak Out. It Isn't the End of the Line for Psychedelic Medicines. -- Barrons.com
By Josh Nathan-Kazis Turn on, tune in, drop in value. A frigid reception for one novel psychedelic treatment by a Food and Drug Administration advisory committee doesn't spell doom for all psychedel
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outwe
Psychedelic Drug Stocks Plummet On FDA Advisers' Doubts About Ecstasy Candidate -- WSJ
By Liz Essley Whyte Stocks for companies developing psychedelic treatments fell Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA,
Comments
$Seelos Therapeutics(SEEL.US$ $Cybin(CYBN.US$ $Mind Medicine(MNMD.US$ FDA advisory panel fails to endorse psychedelic MDMA therapy for PTSD
A panel of advisors to the U.S. FDA declined to endorse Lykos Therapeutics' application to market to psychedelic drug MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder.
The Psychopharmacologic Drugs Advisory Committee held votes on twoquestions. The first dealt was the drug's efficacy in PTSD, while the second aske...
A panel of advisors to the U.S. FDA declined to endorse Lykos Therapeutics' application to market to psychedelic drug MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder.
The Psychopharmacologic Drugs Advisory Committee held votes on twoquestions. The first dealt was the drug's efficacy in PTSD, while the second aske...
5
13
$Mind Medicine(MNMD.US$ i swear my brokerage (not moomoo) knows what stocks i buy and instantly shorts my stock
1
2
$Mind Medicine (MNMD.US)$ all work force buisness owner operators should invest into this companies products. this could not only benifit people with the disorders outlined in their descriptions but think about our work force in general I know for the agency I work for we have call ins all the time and generally speaking it's almost always the same people it isn't just my agency but national, jobs every wherewould benifit. so this company could help everyone every where! This company will ris...
1
$Mind Medicine(MNMD.US$ Mind Medicine Presents New Studies At ISPOR 2024 Showing Growing Burden And Impact Of Generalized Anxiety Disorder In The U.S.
Benzinga· just
GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life-
-People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD-
-Comprehensive Analyses of GAD Disease Burden in the US Conducted by MindMed; Company is Investigating New Treatments...
Benzinga· just
GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life-
-People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD-
-Comprehensive Analyses of GAD Disease Burden in the US Conducted by MindMed; Company is Investigating New Treatments...
1
1
Read more
JESSE JAMES8832 : this isnt even about $cybn ... this stock has had nothing but good news for the last 8 momths and doesnt reallyt budge it lol but some off brand news hits and it goes down lol wtf.. i still believe in this guy tho im stilll here
JESSE JAMES8832 : thanks for update tho brother
TrytosaveabitOP JESSE JAMES8832: I know it doesn’t! I added it only because im starting to see a pattern with schedule 1 drugs even for legit reasons being hammered by the government agencies! Grrrrr
TrytosaveabitOP JESSE JAMES8832: You’re welcome! Sry I didn’t mean to confuse. Guess I shoulda thought it through a bit more? Hehehe! BTW how’s the new gig? Mis not seeing you during the day
JESSE JAMES8832 : hey bro I wasn't coming at you just the way moomoo or whoever orientation the news towards this and it doesn't even pertain to this stock... the gig is goin ok so far.. wasted a whole day yesterday driving down to Mansfield p.a. for lowes to have screwed up the order..
View more comments...